196 related articles for article (PubMed ID: 18160304)
1. Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
Malleo G; Mazzon E; Genovese T; Di Paola R; Caminiti R; Esposito E; Bramanti P; Cuzzocrea S
Cytokine; 2008 Feb; 41(2):136-43. PubMed ID: 18160304
[TBL] [Abstract][Full Text] [Related]
2. Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Caminiti R; Esposito E; Di Bella P; Cuzzocrea S
Shock; 2008 May; 29(5):560-71. PubMed ID: 17724436
[TBL] [Abstract][Full Text] [Related]
3. Absence of peroxisome proliferators-activated receptors (PPAR)alpha enhanced the multiple organ failure induced by zymosan.
Di Paola R; Esposito E; Mazzon E; Genovese T; Muià C; Crisafulli C; Malleo G; Sessa E; Meli R; Cuzzocrea S
Shock; 2006 Nov; 26(5):477-84. PubMed ID: 17047518
[TBL] [Abstract][Full Text] [Related]
4. Role of interleukin-6 in a non-septic shock model induced by zymosan.
Cuzzocrea S; de Sarro G; Costantino G; Mazzon E; Laurà R; Ciriaco E; de Sarro A; Caputi AP
Eur Cytokine Netw; 1999 Jun; 10(2):191-203. PubMed ID: 10400825
[TBL] [Abstract][Full Text] [Related]
5. GITR gene deletion and GITR-FC soluble protein administration inhibit multiple organ failure induced by zymosan.
Galuppo M; Nocentini G; Mazzon E; Ronchetti S; Esposito E; Riccardi L; Di Paola R; Bruscoli S; Riccardi C; Cuzzocrea S
Shock; 2011 Sep; 36(3):263-71. PubMed ID: 21654556
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice.
Jansen MJ; Hendriks T; de Man BM; van der Meer JW; Goris RJ
Cytokine; 1999 Sep; 11(9):713-21. PubMed ID: 10479408
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-10 reduces morbidity and mortality in murine multiple organ dysfunction syndrome (MODS).
Ferrer TJ; Webb JW; Wallace BH; Bridges CD; Palmer HE; Robertson RD; Cone JB
J Surg Res; 1998 Jul; 77(2):157-64. PubMed ID: 9733603
[TBL] [Abstract][Full Text] [Related]
8. A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome.
Jansen MJ; Hendriks T; Hermsen R; Van der Meer JW; Goris RJ
Cytokine; 1998 Nov; 10(11):904-10. PubMed ID: 9878128
[TBL] [Abstract][Full Text] [Related]
9. Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice.
Mondello S; Galuppo M; Mazzon E; Italiano D; Mondello P; Aloisi C; Cuzzocrea S
Eur J Pharmacol; 2011 May; 658(1):28-40. PubMed ID: 21349270
[TBL] [Abstract][Full Text] [Related]
10. The effects of L-NG-nitroarginine in a zymosan-induced multiple organ dysfunction syndrome model.
Ozel H; Yuksel BC; Berkem H; Avsar FM; Guler G; Iskit AB; Guc MO; Hengirmen S
Eur Surg Res; 2009; 43(2):211-8. PubMed ID: 19556797
[TBL] [Abstract][Full Text] [Related]
11. Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice.
Mazzon E; Esposito E; Di Paola R; Impellizzeri D; Bramanti P; Cuzzocrea S
Pharmacol Res; 2011 Jul; 64(1):68-79. PubMed ID: 21193041
[TBL] [Abstract][Full Text] [Related]
12. Role of endogenous interleukin-10 in local and distant organ injury after visceral ischemia-reperfusion.
Welborn MB; Moldawer LL; Seeger JM; Minter RM; Huber TS
Shock; 2003 Jul; 20(1):35-40. PubMed ID: 12813366
[TBL] [Abstract][Full Text] [Related]
13. The effects of selective nitric oxide synthase blocker on survival, mesenteric blood flow and multiple organ failure induced by zymosan.
Tanriverdi P; Yuksel BC; Rasa K; Guler G; Iskit AB; Guc MO; Korkmaz A
J Surg Res; 2005 Mar; 124(1):67-73. PubMed ID: 15734481
[TBL] [Abstract][Full Text] [Related]
14. The tyrosine kinase inhibitor tyrphostin AG 126 reduces the multiple organ failure induced by zymosan in the rat.
Dugo L; Chatterjee PK; Mazzon E; McDonald MC; Paola RD; Fulia F; Caputi AP; Thiemermann C; Cuzzocrea S
Intensive Care Med; 2002 Jun; 28(6):775-88. PubMed ID: 12107686
[TBL] [Abstract][Full Text] [Related]
15. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion.
Patel NS; Chatterjee PK; Di Paola R; Mazzon E; Britti D; De Sarro A; Cuzzocrea S; Thiemermann C
J Pharmacol Exp Ther; 2005 Mar; 312(3):1170-8. PubMed ID: 15572648
[TBL] [Abstract][Full Text] [Related]
16. Ethyl pyruvate reduces the development of zymosan-induced generalized inflammation in mice.
Di Paola R; Mazzon E; Genovese T; Crisafulli C; Bramanti P; Caminiti R; Esposito E; Fink MP; Cuzzocrea S
Crit Care Med; 2009 Jan; 37(1):270-82. PubMed ID: 19050619
[TBL] [Abstract][Full Text] [Related]
17. Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin.
Shayevitz JR; Miller C; Johnson KJ; Rodriguez JL
Shock; 1995 Dec; 4(6):389-96. PubMed ID: 8608394
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of hypertonic saline on peritonitis-induced septic shock with multiple organ dysfunction syndrome in rats.
Shih CC; Chen SJ; Chen A; Wu JY; Liaw WJ; Wu CC
Crit Care Med; 2008 Jun; 36(6):1864-72. PubMed ID: 18496380
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent improvements in outcome with adenoviral expression of interleukin-10 in a murine model of multisystem organ failure.
McAuliffe PF; Murday ME; Efron PA; Scumpia PO; Ungaro R; Abouhamze A; Tannahill CL; Hutchins B; LaFace D; Moldawer LL
Gene Ther; 2006 Feb; 13(3):276-82. PubMed ID: 16251998
[TBL] [Abstract][Full Text] [Related]
20. Tyrphostin AG-490 inhibited the acute phase of zymosan-induced inflammation.
Dimitrova P; Ivanovska N
Int Immunopharmacol; 2008 Nov; 8(11):1567-77. PubMed ID: 18656556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
